No abstract

Since the emergence of COVID-19, thousands of people undergo chest X-ray and computed tomography scan for its screening on everyday basis. This has increased the workload on radiologists, and a number of cases are in backlog. This is not only the case for COVID-19, but for the other abnormalities needing radiological diagnosis as well. In this work, we present an automated technique for rapid diagnosis of COVID-19 on computed tomography images. The proposed technique consists of four primary steps: (1) data collection and normalization, (2) extraction of the relevant features, (3) selection of the most optimal features and (4) feature classification. In the data collection step, we collect data for several patients from a public domain website, and perform preprocessing, which includes image resizing. In the successive step, we apply discrete wavelet transform and extended segmentation-based fractal texture analysis methods for extracting the relevant features. This is followed by application of an entropy controlled genetic algorithm for selection of the best features from each feature type, which are combined using a serial approach. In the final phase, the best features are subjected to various classifiers for the diagnosis. The proposed framework, when augmented with the Naive Bayes classifier, yields the best accuracy of 92.6%. The simulation results are supported by a detailed statistical analysis as a proof of concept.

No abstract

No abstract

: The last couple of months have witnessed the world in a state of virtual standstill. The SARS-CoV-2 virus has overtaken globe to economic and social lockdown. Many patients with COVID-19 have compromised immunity, especially in an aged population suffering from Parkinson disease (PD). Alteration in dopaminergic neurons or deficiency of dopamine in PD patients is the most common symptoms affecting 1% population above the age of 60 years. The compromised immune system and inflammatory manifestation in PD patients make them an easy target. The most common under trial drugs for COVID-19 are Remdesivir, Favipiravir, Chloroquine and Hydroxychloroquine, Azithromycin along with adjunct drugs like Amantadine with some monoclonal antibodies. : Presently, clinically US FDA approved drugs in PD includes Levodopa, catechol-O-methyl transferase (COMT) inhibitors, (Entacapone and Tolcapone), Dopamine agonists (Bromocriptine, Ropinirole, Pramipexole, and Rotigotine), Monoamine oxidase B (MAO-B) inhibitors (Selegiline and Rasagiline), Amantadine and Antimuscarinic drugs. The drugs have established mechanism of action on PD patients with known pharmacodynamics and pharmacokinetic properties along with dose and adverse effects. : Conclusion and relevance of this review focus on the drugs that can be tried for the PD patients with SAR CoV-2 infection, in particular, Amantadine approved by all developed countries a common drug possessing both antiviral properties by downregulation of CTSL, lysosomal pathway disturbance and change in pH necessary to uncoat the viral proteins and antiParkinson properties. The significant prognostic adverse effect of SARS-CoV-2 on PD and the present-day treatment options, clinical presentation and various mechanism is warrant need of the hour.